# NCT04216290 (NCT04216290)

> A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04216290
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Bladder Urothelial Carcinoma; Stage III Bladder Cancer AJCC v8
- Interventions: Biopsy of Bladder; Biospecimen Collection; Cisplatin; Computed Tomography; Cystoscopy; Durvalumab; Fluorouracil; Gemcitabine Hydrochloride; Magnetic Resonance Imaging; Mitomycin; Patient Observation; Radiation Therapy
- Enrollment: 11
- Primary outcome: Clinical complete response (CR)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct04216290